Lupin receives USFDA nod for cholesterol drug
New Delhi: Drug firm Lupin has received approval from the US health regulator to market Pitavastatin tablets used for lowering cholesterol.
In a BSE filing, Lupin said it has received 505 (b) (2) NDA approval for its Nikita Pitavastatin tablets 1mg, 2mg and 4mg from the United States Food and Drug Administration (USFDA).
The company said Nikita tablets are Pitavastatin sodium, an alternate salt product of Kowa Company Ltd's Livalo tablets.
"It is a new option for patients with primary hyperlipidemia or mixed dyslipidemia as an adjunction therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotien B, triglycerides and to increase high-density lipoprotein cholesterol," it said.
As per IMS MAT June 2017 data, Livalo tablets had US sales of USD 272 million, it added.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd